Literature DB >> 23640104

Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.

R Soderquist1, D J P Bates, A V Danilov, A Eastman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23640104      PMCID： PMC4196853          DOI： 10.1038/leu.2013.138

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis.

Authors:  Céline Gélinas; Eileen White
Journal:  Genes Dev       Date:  2005-06-01       Impact factor: 11.361

2.  Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

Authors:  Rong Chen; Lei Guo; Yuling Chen; Yingjun Jiang; William G Wierda; William Plunkett
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

3.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  Induction of LFA-1 independent human B cell proliferation and differentiation by binding of CD40 with its ligand.

Authors:  S Néron; A Pelletier; M C Chevrier; G Monier; R Lemieux; A Darveau
Journal:  Immunol Invest       Date:  1996 Jan-Mar       Impact factor: 3.657

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

7.  Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.

Authors:  L Zhang; H Lopez; N M George; X Liu; X Pang; X Luo
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

8.  An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.

Authors:  Glenn Liu; W Kevin Kelly; George Wilding; Lance Leopold; Kimberli Brill; Bradley Somer
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

9.  Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.

Authors:  Yang Meng; Wenhua Tang; Yao Dai; Xiaoqing Wu; Meilan Liu; Qing Ji; Min Ji; Kenneth Pienta; Theodore Lawrence; Liang Xu
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

10.  Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Authors:  Meike Vogler; Michael Butterworth; Aneela Majid; Renata J Walewska; Xiao-Ming Sun; Martin J S Dyer; Gerald M Cohen
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113
View more
  15 in total

1.  The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.

Authors:  Leisi Zhang; Yong Zhou; Kai Chen; Pengcheng Shi; Yin Li; Manman Deng; Zhiwu Jiang; Xiangmeng Wang; Peng Li; Bing Xu
Journal:  Target Oncol       Date:  2017-10       Impact factor: 4.493

2.  The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-κB activation and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  J Claire Godbersen; Leigh Ann Humphries; Olga V Danilova; Peter E Kebbekus; Jennifer R Brown; Alan Eastman; Alexey V Danilov
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

3.  Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.

Authors:  S L Khaw; D Mérino; M A Anderson; S P Glaser; P Bouillet; A W Roberts; D C S Huang
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

4.  Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts.

Authors:  Alexey V Danilov; Ryan S Soderquist; Darcy J P Bates; Alan Eastman
Journal:  Expert Rev Anticancer Ther       Date:  2013-09       Impact factor: 4.512

Review 5.  Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Authors:  Alexey V Danilov
Journal:  Clin Ther       Date:  2013-09       Impact factor: 3.393

Review 6.  BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.

Authors:  Ryan S Soderquist; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2016-08-17       Impact factor: 6.261

7.  Nuphar alkaloids induce very rapid apoptosis through a novel caspase-dependent but BAX/BAK-independent pathway.

Authors:  David J Mallick; Alexander Korotkov; Hui Li; Jimmy Wu; Alan Eastman
Journal:  Cell Biol Toxicol       Date:  2019-03-02       Impact factor: 6.691

8.  Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.

Authors:  Ryan S Soderquist; Alexey V Danilov; Alan Eastman
Journal:  J Biol Chem       Date:  2014-04-28       Impact factor: 5.157

9.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

Review 10.  Broad targeting of resistance to apoptosis in cancer.

Authors:  Ramzi M Mohammad; Irfana Muqbil; Leroy Lowe; Clement Yedjou; Hsue-Yin Hsu; Liang-Tzung Lin; Markus David Siegelin; Carmela Fimognari; Nagi B Kumar; Q Ping Dou; Huanjie Yang; Abbas K Samadi; Gian Luigi Russo; Carmela Spagnuolo; Swapan K Ray; Mrinmay Chakrabarti; James D Morre; Helen M Coley; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; William G Helferich; Xujuan Yang; Chandra S Boosani; Gunjan Guha; Dipita Bhakta; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; W Nicol Keith; Alan Bilsland; Dorota Halicka; Somaira Nowsheen; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2015-04-28       Impact factor: 15.707
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.